Seven Eight Capital, LP Natera, Inc. Transaction History

Seven Eight Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$85.28 - $112.6 $391,008 - $516,271	4,585 New	4,585 $496,000
Q2 2022 Aug 04, 2022	SELL	$28.13 - $44.54 $338,544 - $536,038	-12,035 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$30.32 - $91.33 $364,901 - $1.1 Million	12,035 New	12,035 $490,000
Q4 2021 Feb 14, 2022	SELL	$86.26 - $119.0 $535,329 - $738,514	-6,206 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$100.17 - $126.36 $130,922 - $165,152	1,307 Added 26.68%	6,206 $692,000
Q2 2021 Aug 13, 2021	BUY	$86.05 - $119.72 $421,558 - $586,508	4,899 New	4,899 $556,000
Q2 2020 Aug 06, 2020	SELL	$26.36 - $49.86 $429,457 - $812,319	-16,292 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$17.27 - $40.17 $691,991 - $1.61 Million	-40,069 Reduced 71.09%	16,292 $486,000
Q4 2019 Feb 13, 2020	BUY	$32.1 - $40.4 $677,310 - $852,440	21,100 Added 59.84%	56,361 $1.9 Million
Q3 2019 Nov 14, 2019	BUY	$25.38 - $34.89 $894,924 - $1.23 Million	35,261 New	35,261 $1.16 Million

526

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.2B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.